Clinical Trial Update: LEVOSIMENDAN to Facilitate Weaning From ECMO in Severe Cardiogenic Shock Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating levosimendan to facilitate weaning from ECMO in patients with severe cardiogenic shock has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiogenic Shock

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication | Phase 3 | Status: COMPLETED